London · Delayed Price · Currency is GBP · Price in GBX 4basebio Company Description
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally.
The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccines and therapeutics; and oeDNA, or open ended DNA, a linear, double stranded DNA product ideal for genome editing.
It also provides osDNA, or open stabilized DNA, a product incorporating nucleotide modifications within the DNA backbone enables tuning of the immunostimulatory properties of the construct for DNA vaccine applications; and The Hermes, a proprietary delivery platform for nucleic acid and protein payloads appears to offer a thermo-stable alternative to traditional lipid based delivery systems.
The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021.
4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
| Country | United Kingdom |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Heikki Lanckriet |
Contact Details
Address: 25 Norman Way Cambridge, CB24 5QE United Kingdom | |
| Phone | 44 1223 967 943 |
| Website | 4basebio.com |
Stock Details
| Ticker Symbol | 4BB |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BMCLYF79 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Heikki Lanckriet | Chief Executive Officer |
| David Roth | Chief Financial Officer |
| Amy Walker | Chief Operating Officer |